Not yet recruiting
Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases
Not yet recruitingRegistered drug
Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases
Registered drug
- Substances:Efgartigimod Alfa
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Efgartigimod Alfa
- Sponsor:Medizinische Hochschule Hannover

